Louisiana Lawsuit Challenges FDA Dispensing Rules for Mifepristone
What happened
A lawsuit filed by Louisiana challenges federal dispensing rules for abortion medication, arguing that remote prescribing and mailing undermine the state's abortion ban. The FDA is conducting a review of mifepristone, which examines whether patients must again obtain the drug in person. The FDA expects to receive study results by mid-December 2026 and complete its review by March 2027.
From rawstory.com
Why it matters
The review, which is part of efforts by the Donald Trump administration, could lead to changes in the Mifepristone REMS Program. The FDA's decision on dispensing rules is being challenged by Louisiana, which seeks to enforce its state abortion ban.
From rawstory.com
Who's involved
- FDAThe regulatory agency reviewing mifepristone and dispensing rules.
- Donald TrumpThe administration whose efforts are laying groundwork for a potential crackdown on abortion medication.
- LouisianaThe state filing a lawsuit challenging federal drug dispensing rules.
Keep exploring
The entities involved
- FDA
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Louisiana
state of the United States of America
Related events
- Trump's organization has been involved in legal challenges in Florida, including a lawsuit filed against the US government.
- The Trump administration proposed cuts to HIV funding.
- Lawsuits and rulings challenge vaccine advisory panel recommendations and quorum, involving Donald Trump and the American Academy of Pediatrics.